BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, January 15, 2026
Home » Authors » Jim Stommen

Jim Stommen

Articles

ARTICLES

The MDD Interview: Size, geographic fit are key in hospitals consolidation

Aug. 30, 2013
By Jim Stommen

The MDD Interview: Modulating risk seen as key in hospitals' merger mania

Aug. 22, 2013
By Jim Stommen

The MDD Interview: Browning: Regulating electronic interfaces is can of worms for FDA

Aug. 15, 2013
By Jim Stommen

Deals roundup: Medtronic says Cardiocom advances its push on services

Aug. 13, 2013
By Jim Stommen

The MDD Interview: Change is imminent as FDA, industry forge new relationship

Aug. 8, 2013
By Jim Stommen

The MDD Interview: Ongoing mentoring builds upon lessons of initial training for vets

Aug. 1, 2013
By Jim Stommen

The MDD Interview: Returning veterans are focus of 'jobs in med-tech' program

July 25, 2013
By Jim Stommen

The MDD Interview: Schain: Market opportunity for CampusMD is almost limitless

July 18, 2013
By Jim Stommen
Devin Schain is the co-founder and CEO of CampusMD (Bethesda, Maryland), a provider of telemedicine-based services. CampusMD is underwritten by HealthNation, a nationwide telehealth service with an independent network of licensed physicians across the U.S., providing participating students with 24/7 access to U.S.-based, licensed physicians via telephone, online video and secure e-mail. Schain has founded and led several companies in the education space, launching his first as an undergraduate at the University of Pennsylvania. Schain now heads CampusDirect, a portfolio company that includes CampusMD among its businesses.
Read More

The MDD Interview: CampusMD uses telemedicine to help fill college health gaps

July 11, 2013
By Jim Stommen
Devin Schain is the co-founder and CEO of CampusMD (Bethesda, Maryland), a provider of telemedicine-based services. CampusMD is underwritten by HealthNation, a nationwide telehealth service with an independent network of licensed physicians across the U.S., providing participating students with 24/7 access to U.S.-based, licensed physicians via telephone, online video and secure e-mail. Schain has founded and led several companies in the education space, launching his first as an undergraduate at the University of Pennsylvania. He now heads CampusDirect, a portfolio company that includes CampusMD among its businesses.
Read More

The MDD Interview: Presence of other players doesn't diminish opportunities in epilepsy

July 3, 2013
By Jim Stommen
View All Articles by Jim Stommen

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 15, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 14, 2026.
  • 3D rendering of antibody drug conjugated with cytotoxic payload

    ADCs’ breakout 2025 and their still-unfinished potential

    BioWorld
    Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
  • Lung cancer illustration

    LINC01116 has prognostic value in lung cancer, study shows

    BioWorld MedTech
    Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing